Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Multicentre Post-exposure Prophylaxis Clinical Trial Evaluating RESP301, an Inhaled Therapy for Treatment of Lung Infections, for Prevention of Onward Transmission of Viral Infections Including SARS-CoV-2 to Household Members

NCT04842331 is registered in ClinicalTrials.gov with Thirty Respiratory Limited as lead sponsor.

NCT NCT04842331
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04842331 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Multicentre Post-exposure Prophylaxis Clinical Trial Evaluating RESP301, an Inhaled Therapy for Treatment of Lung Infections, for Prevention of Onward Transmission of Viral Infections Including SARS-CoV-2 to Household Members
Lead sponsor
Thirty Respiratory Limited
Phase
Phase 2/3
Overall status
Withdrawn
Start date
September 30, 2021
Completion date
January 31, 2022
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 respiratory infection, respiratory tract diseases, respiratory viral infection